论文部分内容阅读
目的观察贝那普利与缬沙坦双重阻断肾素-血管紧张素系统(RAS)治疗糖尿病肾病的临床疗效。方法选取遵化市人民医院于2010年5月至2012年3月收治的122例糖尿病肾病患者作为研究对象,将其分为治疗组、对照组1与对照组2。其中,治疗组40例,利用贝那普利联合缬沙坦治疗,对照组1有患者41例,采用贝那普利进行治疗,对照组2有患者41例,采用缬沙坦进行治疗。在治疗3个月后测量患者的尿蛋白排泄率(UP-ER)等指标,在治疗后的3个月后对患者进行6个月的随访。结果三组患者在治疗后尿蛋白排泄率(UPER)均呈下降趋势,但治疗组的下降趋势更明显、更快,在治疗后的9个月内治疗组、对照组1、对照组2的肾脏累积生存率分别为60.2%、67.3%和88.5%。结论采用贝那普利与缬沙坦治疗均能提高糖尿病肾病患者的肾功能,但是将两者联合使用的效果明显优于两组单独使用的效果。
Objective To observe the clinical efficacy of benazepril combined with valsartan in the treatment of diabetic nephropathy by dual renin-angiotensin system (RAS). Methods A total of 122 patients with diabetic nephropathy admitted from May 2010 to March 2012 in Zunhua People’s Hospital were divided into treatment group, control group 1 and control group 2. Among them, the treatment group 40 cases, the use of benazepril combined with valsartan treatment, control group 1 patients with 41 cases, the use of benazepril treatment, control group 2 patients with 41 cases, the use of valsartan for treatment. The urinary protein excretion rate (UP-ER) was measured in 3 months after treatment and patients were followed up for 6 months after 3 months. Results The urinary protein excretion rate (UPER) of the three groups showed a decreasing trend after treatment, but the decreasing trend of the treatment group was more obvious and faster. Within 9 months after treatment, the treatment group, the control group 1, the control group 2 The cumulative renal survival rates were 60.2%, 67.3% and 88.5%, respectively. Conclusion Both benazepril and valsartan treatment can improve renal function in patients with diabetic nephropathy, but the combination of the two is obviously better than the two groups alone.